NCT00919399

Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant

Phase II Study Evaluating the Effectiveness of the Exemestane (Aromasin) With Tamoxifen on the Rate of Clinical Response Menopausal in Patients With Locally Advanced Breast Tumors

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Institut Claudius Regaud · Academic / Other
• Sex: Female
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase II non-randomized, open, uncontrolled and bi-centric study of hormonal induction by exemestane (Aromasin) + tamoxifen to evaluate the effectiveness of exemestane (Aromasin) with tamoxifen on the rate of clinical response menopausal in patients with tumors of locally advanced breast. Hormone therapy will be administered at a dose of 25mg/day for exemestane and 20 mg / day for 4 months for tamoxifen.

Conditions

• Breast Neoplasms

Interventions

Type	Name	Description
DRUG	Exemestane	25mg a day during 4 months
DRUG	tamoxifen	One 20 mg tablet a day started 1 week after the first Aromasine intake

Timeline

• Start date: 2002-01-01
• Primary completion: 2006-06-01
• Completion: 2006-06-01
• First posted: 2009-06-12
• Last updated: 2009-06-12

Locations

2 sites across 1 country: France